



Dr. Maria Elsa Gambuzza - Italian Ministry of Health of Infectious Diseases.

### Education

- Degree in Biology;
- Postdegree in Medical Microbiology and Virology
- PhD in:  
“Clinical Neuroscience;  
“Microbial Biotechnology “  
” Work’s medicine”.

### Recent Publications

1. Soraci L, **Gambuzza ME**, Biscetti L, Laganà P, Lo Russo C, Buda A, Barresi G, Corsonello A, Lattanzio F, Lorello G, Filippelli G, Marino S.J Neurol. 2023 Mar;270(3):1346-1360. doi: 10.1007/s00415-022-11491-3.
2. Soraci L, Cherubini A, Paoletti L, Filippelli G, Luciani F, Laganà P, **Gambuzza ME**, Filicetti E, Corsonello A, Lattanzio F. Safety and Tolerability of Antimicrobial Agents in the Older Patient
3. Drugs Aging. 2023 Jun;40(6):499-526. doi: 10.1007/s40266-023-01019-3.
4. Gambuzza et al.. COVID-19 Vaccines: Current and Future Perspectives. Review. Vaccines, 7 April 2022, 10, 608.
5. Gambuzza et al.. Phenolic substances in foods and anticarcinogenic properties: a public health perspective. J of AOAC Int., 1 Jul 2020; 103(4): 935-39.
6. Gambuzza et al.. Legionella risk assessment in cruise ships and ferries. Ann Agr. Env Med 2/2017 vol. 24.
7. Gambuzza et al.. Innate Immune Surveillance in the Central Nervous System Following *Legionella pneumophila* Infection. CNS Neurol Disord Drug Targets. 16 Nov 2017;16(10):1080-1089. doi: 10.2174/187152731666171123210420. Review.
8. Gambuzza et al.. Stroke and the immune system: therapeutic targeting of Toll-like receptors. Ch. III – Book New Concepts in Stroke Diagnosis and Therapy. Ed. A. Radaelli et al. 17 Feb. 2017. eISBN: 9781681084213
9. Gambuzza et al.. Toll-like Receptor 3-Agonists as Promising Candidates in Alzheimer’s Disease. The Lancet Neurology Conference – 19-21 Ottobre 2016 – London – Poster.
10. Gambuzza et al.. A new era for immunotherapeutic approaches in Multiple Sclerosis treatment. J Clin Trials, 23 Dec 2015
11. Gambuzza et al.. A TLR3 agonist as promising candidate in multiple sclerosis management. J Clinic Cell Immunol 2015, 6:4.
12. Gambuzza et al.. . The Role of Toll-like Receptors in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis: A New Promising Therapeutic Approach? CNS Neurol Disord Drug Targets. 23 Mar 2015 Mar 25. [Epub ahead of print]
13. Gambuzza et al.. Parkinson’s disease: therapeutic targeting of Toll-like receptors. Poster ADPD - Nice, 18 March 2015.
14. **G** Gambuzza et al.: Toll-Like Receptors in Alzheimer’s Disease: a Therapeutic Perspective CNS Neurol Disord Drug Targets. 2014, 13:1542-58.

AA 2021/2022: Attività didattica nell’ambito del Master d’II livello in “Hospital acquired infections, antimicrobial stewardship and pandemics: prevention, control and preparedness – II Ed.

Messina, 21 Giugno 2023

Maria Elsa Gambuzza